Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: An analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial

American Heart Journal

Volumn 152, Issue 1, 2006, Pages 149-154

  Rajagopal, Vivek ^a   Lincoff, A Michael ^a   Cohen, David J ^b   Gurm, Hitinder S ^a   Hu, Tingfei ^a   Desmet, Walter J ^c   Kleiman, Neal S ^d   Bittl, John A ^e   Feit, Frederick ^f   Topol, Eric J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c UH Gasthuisberg ^*  (Belgium)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e Ocala Heart Institute   (United States)

^f NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANALYSIS; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DISEASE SEVERITY; DRUG EFFICACY; EVALUATION; FEMALE; HEALTH CARE COST; HEALTH ECONOMICS; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

AGED; ANGINA, UNSTABLE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; ANTITHROMBINS; COMBINED MODALITY THERAPY; DRUG THERAPY, COMBINATION; FEMALE; HEPARIN; HIRUDINS; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PEPTIDE FRAGMENTS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RANDOMIZED CONTROLLED TRIALS; RECOMBINANT PROTEINS; SYNDROME; TREATMENT OUTCOME; UNITED STATES;

EID: 33745675382     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2005.09.007     Document Type: Article

References (16)

1. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 330 (1994) 956-961
2. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 336 (1997) 1689-1696
3. Bhatt D.L., and Topol E.J. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. JAMA 284 (2000) 1549-1558
4. Lincoff A.M., Califf R.M., Anderson K.M., et al. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Complications. J Am Coll Cardiol 30 (1997) 149-156
5. Anderson K.M., Califf R.M., Stone G.W., et al. Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol 37 (2001) 2059-2065
6. Bittl J.A., Chaitman B.R., Feit F., et al. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J 142 (2001) 952-959
7. Lincoff A.M., Bittl J.A., Harrington R.A., et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 289 (2003) 853-863
8. Cohen D.J., Lincoff A.M., Lavelle T.A., et al. Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial. J Am Coll Cardiol 44 (2004) 1792-1800
9. Cohen D.J., Krumholz H.M., Sukin C.A., et al. In-hospital and one-year economic outcomes after coronary stenting or balloon angioplasty. Results from a randomized clinical trial. Stent Restenosis Study Investigators. Circulation 92 (1995) 2480-2487
10. Taira D.A., Seto T.B., Siegrist R., et al. Comparison of analytic approaches for the economic evaluation of new technologies alongside multicenter clinical trials. Am Heart J 145 (2003) 452-458
11. Newby L.K., Ohman E.M., Christenson R.H., et al. Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin T-positive status: the paragon-B troponin T substudy. Circulation 103 (2001) 2891-2896
12. Bittl J.A., Strony J., Brinker J.A., et al. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators. N Engl J Med 333 (1995) 764-769
13. Lefkovits J., and Topol E.J. Direct thrombin inhibitors in cardiovascular medicine. Circulation 90 (1994) 1522-1536
14. Shojania A.M., and Turnbull G. Effect of heparin on platelet count and platelet aggregation. Am J Hematol 26 (1987) 255-262
15. Weitz J.I., Hudoba M., Massel D., et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 86 (1990) 385-391
16. Weitz J.I., and Bates S.M. Acute coronary syndromes: a focus on thrombin. J Invasive Cardiol 14 Suppl B (2002) 2B-7B